ClinicalTrials.gg
CompletedNCT02490852Updated May 21, 2019

Study of Nutritional Suitability of a New Infant Formula for Term Infants

An interventional study of Investigational infant formula and Active Comparator: Commercially available Infant formula in Growth, sponsored by Ausnutria Hyproca B.V.. Completed at 18 sites in 4 countries. Open to participants aged Up to 13 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-21.

Sponsored by Ausnutria Hyproca B.V. · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
Up to 13 Days
Sex
All
01

Study summary

This is a growth study of full-term infants. The growth of infants fed the investigational formula will be compared with infants fed a control formula. A breastfeeding arm will be used as reference.

02

Conditions studied

  • Growth
03

In context

Lead sponsor

Ausnutria Hyproca B.V. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 13 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy full term infant (37-42 weeks of gestational age)
  • Birth weight 2,500 to 4,500 g
  • Infant's mother willing and able to exclusively breast feed or infant's parent(s)/caregiver(s) willing to exclusively use randomized infant formula during study participation
  • Parent(s)/caregiver(s) able to attend visits and willing to complete the subject diary
  • signed by parent(s)/caregiver(s)

Exclusion criteria

Exclusion Criteria:

  • Congenital illness or malformation that may affect infant feeding or normal growth
  • Gastrointestinal disorders
  • Suspected or known allergy to milk protein for formula groups
  • Known food allergies in parents or siblings for formula groups
  • Multiples
  • Readmission to hospital for longer than 3 days for another reason than hyperbilirubinemia prior to enrollment
  • Infant participating in another clinical study
  • Infant's family unable to comply with the protocol according to the investigators's assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    Investigational Infant formula

    Healthy term infants fed exclusively the investigational Infant Formula

    Other: Investigational infant formula

  • Active comparator
    Commercially available Infant formula

    Healthy term infants fed exclusively a commercially available Infant Formula

    Other: Active Comparator: Commercially available Infant formula

  • Active comparator
    Human milk

    Healthy term infants fed exclusively human milk

    Other: Active Comparator: Human milk

Interventions

  • OtherInvestigational infant formula

    fed ad libitum

  • OtherActive Comparator: Commercially available Infant formula

    fed ad libitum

  • OtherActive Comparator: Human milk

    fed ad libitum

06

What researchers measure

Primary outcomes

  1. Weight gain

    Time frame: 16 weeks

07

Study locations

18 sites
  • Vienna, Austria
  • Dakovo, Croatia
  • Dubrovnik, Croatia
  • Kutina, Croatia
  • Split, Croatia
  • Vukovar, Croatia
  • Zadar, Croatia
  • Zagreb, Croatia
  • Zapresic, Croatia
  • Bramsche, Germany
  • Hamm, Germany
  • Herford, Germany
  • Mannheim, Germany
  • Monchengladbach, Germany
  • Wesel, Germany
  • Wuppertal, Germany
  • Barcelona, Spain
  • Madrid, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Aug 2018 and a completion of Aug 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2015
First posted
Jul 7, 2015
Start
Aug 2015
Primary completionActual
Aug 22, 2018
CompletionActual
Aug 22, 2018
Last update
May 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02490852
Lead sponsor
Ausnutria Hyproca B.V.
Responsible party
Sponsor
First posted
Jul 7, 2015
Start date
Aug 2015
Primary completion
Aug 22, 2018
Completion
Aug 22, 2018
Last update
May 21, 2019

Study contacts

Falco Panzer, Dr. Med.
principal investigator · Kinderärztliche Gemeinschaftspraxis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion